Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medical Device Labeling Regulations, 16824-16827 [05-6405]
Download as PDF
<![CDATA[
16824
Federal Register / Vol. 70, No. 62 / Friday, April 1, 2005 / Notices
Dated: March 29, 2005.
Patricia A. Morrissey,
Commissioner, Administration on
Developmental Disabilities.
[FR Doc. 05–6483 Filed 3–31–05; 8:45 am]
BILLING CODE 4184–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2004N–0515]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Medical Device
Labeling Regulations
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by May 2,
2005.
OMB is still experiencing
significant delays in the regular mail,
including first class and express mail,
and messenger deliveries are not being
accepted. To ensure that comments on
the information collection are received,
OMB recommends that comments be
faxed to the Office of Information and
Regulatory Affairs, OMB, Attn: Fumie
Yokota, Desk Officer for FDA, FAX:
202–395–6974.
FOR FURTHER INFORMATION CONTACT:
Peggy Robbins, Office of Management
Programs (HFA–250), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–1223.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
ADDRESSES:
Medical Device Labeling Regulations—
21 CFR Parts 800, 801, and 809 (OMB
Control Number 0910–0485)—Extension
Section 502 of the Federal Food, Drug,
and Cosmetic Act (the act) (21 U.S.C.
352), among other things, establishes
requirements for the label or labeling of
a medical device so that it is not
misbranded and subject to regulatory
action. Certain provisions of section 502
of the act require that manufacturers,
importers, and distributors of medical
VerDate jul<14>2003
17:15 Mar 31, 2005
Jkt 205001
devices disclose information about
themselves or their devices on the labels
or labeling of the devices. Section 502(b)
of the act requires that, if the device is
in a package, the label must contain the
name and place of business of the
manufacturer, packer, or distributor and
an accurate statement of the quantity of
the contents. Section 502(f) of the act
provides that the labeling of a device
must contain adequate directions for
use. FDA may grant an exemption from
the adequate directions for use
requirement, if FDA determines that
adequate directions for use are not
necessary for the protection of the
public health.
FDA regulations in parts 800, 801,
and 809 (21 CFR parts 800, 801, and
809) require manufacturers, importers,
and distributors of medical devices to
disclose to health professionals and
consumers specific information about
themselves or their devices on the label
or labeling of their devices. FDA issued
these regulations under the authority of
sections 201, 301, 502, and 701 of the
act (21 U.S.C. 321, 331, 352, and 371).
Most of the regulations in parts 800,
801, and 809 derive from the
requirements of section 502 of the act,
which provides, in part, that a device
shall be misbranded if, among other
things, its label or labeling fails to bear
certain required information concerning
the device, is false or misleading in any
particular way, or fails to contain
adequate directions for use.
Section 800.12 requires that packages
of contact lens cleaning solutions
include a tamper-resistant feature to
prevent malicious adulteration. Sections
800.10(a)(3) and 800.12(c) require that
the label of contact lens cleaning
solutions contain a prominent statement
alerting consumers to the tamperresistant feature.
Section 800.10(b)(2) requires that the
labeling of liquid ophthalmic
preparations packed in multiple-dose
containers include information as to
duration of use and necessary warnings
to afford adequate protection from
contamination during use.
Section 801.1 requires that the label of
a device in package form contain the
name and place of business of the
manufacturer, packer, or distributor.
Section 801.5 requires that the
labeling of devices include directions
under which the layman can use a
device safely and for the purposes for
which it is intended. Section 801.4
defines ‘‘intended use’’. Where
necessary, the labeling should include:
(1) Statements of all conditions,
purposes, or uses for which the device
is intended, unless the device is a
prescription device subject to the
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
requirements of § 801.109; (2) quantity
of dose; (3) frequency of administration
or application; (4) duration of
administration or application; (5) time
of administration, e.g. in relation to
meals, onset of symptoms, etc.; (6) route
of method or application; and (7)
preparation for use.
Section 801.61 requires that the
principal display panel of an over-thecounter (OTC) device in package form
must include a statement of the identity
of the device. The statement of the
identity of the device must include the
common name of the device followed by
an accurate statement of the principal
intended actions of the device.
Section 801.62 requires that the label
of an OTC device in package form must
include a declaration of the net quantity
of contents. The label must express the
net quantity in terms of weight,
measure, numerical count, or a
combination of numerical count and
weight, measure, or size.
Section 801.109 establishes labeling
requirements for prescription devices. A
prescription device is defined as a
device which, because of its potential
for harmful effect, the method of its use
or the collateral measures necessary to
its use, is not safe except under the
supervision of a practitioner licensed by
law to use the device and, therefore, for
which adequate directions for use by a
layperson cannot be developed.
The label of the device must include:
(1) The statement ‘‘Caution: Federal law
restricts this device to sale by or on the
order of a ‘______’ ’’. The blank is to be
filled in by a term such as ‘‘physician,’’
‘‘dentist,’’ or other appropriate term;
and (2) the method of its application or
use.
Labeling must include information for
use, including indications, effects,
routes, methods, frequency and duration
of administration, and any relevant
hazards, contraindications, side effects,
and precautions under which
practitioners licensed by law to
administer the device can use the device
safely and for the purpose for which it
is intended, including all purposes for
which it is advertised or represented.
Information may be omitted from the
dispensing package if, but only if, the
article is a device for which directions,
hazards, warnings, and other
information are commonly known to
practitioners licensed by law to use the
device.
Section 801.110 establishes a labeling
requirement for a prescription device
delivered to the ultimate purchaser or
user upon the prescription of a licensed
practitioner. The device must be
accompanied by labeling bearing the
name and address of the licensed
E:\FR\FM\01APN1.SGM
01APN1
Federal Register / Vol. 70, No. 62 / Friday, April 1, 2005 / Notices
practitioner and the directions for use
and cautionary statements, if any,
contained in the order.
Section 801.405 establishes labeling
requirements for articles intended for
lay use in repairing and refitting
dentures. The labeling must: (1) Limit
directions for use for denture repair kits
to emergency repair pending
unavoidable delay in obtaining
professional reconstruction of the
denture; (2) limit directions for use for
denture reliners, pads, and cushions to
temporary refitting pending unavoidable
delay in obtaining professional
reconstruction of the denture; and (3)
contain the word ‘‘emergency’’
preceding and modifying each
indication-for-use statement for denture
repair kits and the word ‘‘temporary’’
preceding and modifying each
indication-for-use statement for reliners,
pads, and cushions.
Section 801.410(f) requires that
results of impact tests and description of
the test method and apparatus be kept
for a period of 3 years.
Section 801.410(f) is designed to
protect the eyeglass wearer from
potential eye injury resulting from
shattering of ordinary eyeglass lenses
and requires that eyeglasses and
sunglasses be fitted with impactresistant lenses. Examination of data
available on the frequency of eye
injuries resulting from the shattering of
ordinary crown glass lenses indicates
that the use of such lenses constitutes
an avoidable hazard to the eye of the
wearer. According to the Vision Council
of America, 60 percent of the
population, or 161 million Americans,
wear prescription eyewear; 81 percent
have eyeglasses, 3 percent have contact
lenses only; and 16 percent have both
eyeglasses and contact lenses.
Section 801.420(c) requires that the
manufacturers or distributors of hearing
aids develop a User Instructional
Brochure, which accompanies the
device and is provided to the
prospective user by the dispenser of the
hearing aid. The brochure must contain
detailed information on the use and
maintenance of the hearing aid.
Section 801.421(b) requires the
hearing aid dispenser to provide the
prospective user a copy of the User
Instructional Brochure and an
opportunity to review the comments
with him/her orally or in the
predominant method of communication
used during the sale.
Section 801.421(c) requires the
hearing aid dispenser to provide, upon
request, to the prospective purchaser of
any hearing aid (s)he dispenses, a copy
of the User Instructional Brochure or the
name and address of the manufacturer
VerDate jul<14>2003
17:15 Mar 31, 2005
Jkt 205001
or distributor from whom the brochure
may be obtained.
Section 801.421(d) requires the
hearing aid dispenser to retain copies of
all physician statements or any waivers
of medical evaluation for 3 years from
the time of dispensing.
Section 801.435 requires condom
manufacturers to include an expiration
date in the labeling of the condom. The
manufacturer must support the
expiration date by data from quality
control tests demonstrating physical and
mechanical integrity of three random
lots of the same product which were
stored under accelerated and real time
conditions.
Section 809.10(a) provides that a label
for an in vitro diagnostic product must
contain the following information:
1. The proprietary and established
name;
2. The intended use or uses of the
product;
3. For a reagent, a declaration of the
established name, if any, and the
quantity, proportion, and concentration
of each reactive ingredient;
4. A statement of warnings and
precautions for users;
5. For a reagent, appropriate storage
instructions;
6. For a reagent, a means by which the
user may be assured that the product
meets the appropriate standards of
identity, strength, quality, and purity;
7. For a reagent, a declaration of the
net quantity of contents;
8. Name and place of business of the
manufacturer, packer, and distributor;
and
9. A lot or control number.
Section 809.10(b) provides that the
labeling (package insert) accompanying
the device must contain the following:
1. Proprietary name and established
name, if any;
2. The intended use or uses;
3. A summary and explanation of the
test;
4. The chemical, physical,
physiological, or biological principles of
the procedure;
5. Information about the reagents;
6. Information about the instruments;
7. Information about the specimen
collection and preparation for analysis;
8. Information about the procedure;
9. Information about the results;
10. Information about the limitations
of the procedure;
11. Expected values;
12. Specific performance
characteristics;
13. A bibliography of pertinent
references; and
14. Date of issuance of the last
revision of the labeling.
Section 809.10(d) provides that the
labeling for general purpose laboratory
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
16825
reagents may be exempt from the
labeling requirements in § 809.10(a) and
(b), if the labeling contains the
following:
1. The proprietary name and
established name of the reagent;
2. The established name and the
quantity, proportion, and concentration
of the reagent ingredient;
3. A statement of the purity and
quality of the reagent;
4. A statement of warnings and
precautions for users;
5. Appropriate storage instructions;
6. A declaration of the net quantity of
contents;
7. Name and place of business of the
manufacturer, packer, or distributor;
and
8. A lot or control number.
Section 809.10(e) requires
manufacturers of analyte specific
reagents to include the following in the
labeling:
1. The proprietary name and
established name, if any, of the reagent;
2. A declaration of established name,
if any, and quantity, proportion or
concentration of the reagent ingredient;
3. A statement of the purity and
quality of the reagent;
4. A statement of warnings or
precautions for users;
5. Appropriate storage instructions;
6. A declaration of the net quantity of
contents;
7. Name and place of business of the
manufacturer, packer, or distributor;
8. A lot or control number; and
9. The statement, ‘‘For analyte
specific reagent use only. Analytical and
performance characteristics are not
established.’’
Section 809.10(f) requires that the
labeling for OTC test sample collection
systems for drugs of abuse testing bear
the following information in a language
appropriate for the intended users:
1. Adequate instructions for specimen
collection and handling;
2. An identification system to ensure
that specimens are not mixed up or
otherwise misidentified at the
laboratory;
3. The intended use or uses of the
product;
4. A statement that confirmatory
testing will be conducted on all samples
that initially test positive;
5. A statement of warnings or
precautions for users;
6. Adequate instructions on how to
obtain test results from a person who
can explain their meaning, including
the probability of false positive and false
negative results, as well as how to
contact a trained health professional if
additional information on interpretation
of test results or followup counseling is
desired; and
E:\FR\FM\01APN1.SGM
01APN1
16826
Federal Register / Vol. 70, No. 62 / Friday, April 1, 2005 / Notices
7. Name and place of business of the
manufacturer, packer, or distributor.
Section 809.30(d) requires that
manufacturers of analyte specific
reagents (ASRs) assure that advertising
and promotional materials for ASRs:
1. Include the identity and purity of
the ASR and the identity of the analyte;
and
2. Do not include any statement
regarding analytical or clinical
performance.
These estimates are based on FDA’s
registration and listing database for
medical device establishments, agency
communications with industry, and
FDA’s knowledge of and experience
with device labeling. We have not
estimated a burden for those
requirements where the information to
be disclosed is information that has
been supplied by FDA. Also, we have
not estimated a burden for that
information that is disclosed to third
parties as a usual and customary part of
a medical device manufacturer,
distributor, or importer’s normal
business activities. We do not include
any burden for time that is spent
designing labels to improve the format
or presentation.
In the Federal Register of December
14, 2004 (69 FR 74529), FDA published
a 60-day notice requesting public
comment on the information collection
provisions. No comments were received.
FDA estimates the burden of this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
21 CFR Section
No. of Respondents
Annual Responses Per Respondent
Total Annual
Responses
Hours per Response
Total Hours
800.10(a)(3) and 800.12(c)
4
10
40
1
40
800.10(b)(2)
4
10
40
40
1,600
801.1
30,000
3.5
105,000
0.1
10,500
801.5
5,000
3.5
17,500
22.35
391,125
801.61
5,000
3.5
17,500
1
17,500
801.62
1,000
5
5,000
1
5,000
801.109
18,000
801.110
10,000
801.405(b)
63,000
17.77
1,119,510
50
500,000
0.25
125,000
40
1
40
4
160
801.420(c)
275
5
1,375
40
55,000
801.421(b)
10,000
160
1,600,000
0.30
480,000
801.421(c)
10,000
5
50,000
0.17
8,500
135
1
135
96
12,960
1,700
6
10,200
80
816,000
809.10(d)
300
2
600
40
24,000
809.10(e)
300
25
7,500
1
7,500
809.10(f)
20
1
20
100
2,000
809.30(d)
300
25
7,500
1
7,500
801.435
809.10(a) and (b)
3.5
Total Burden Hours
1 There
3,083,895
are no capital costs or operating and maintenance costs associated with this information collection.
TABLE 2.—ESTIMATED ANNUAL RECORDKEEPING BURDEN1
21 CFR Section
No. of Recordkeepers
Annual Frequency of Recordkeeping
Total Annual
Records
801.410(f)
30
769,000
23,070,000
801.421(d)
10,000
160
Hours per Recordkeeper
641
1,600,000
0.25
Total Hours
1 There
19,225
400,000
419,225
are no capital costs or operating and maintenance costs associated with this information collection.
VerDate jul<14>2003
Total hours
17:15 Mar 31, 2005
Jkt 205001
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
E:\FR\FM\01APN1.SGM
01APN1
Federal Register / Vol. 70, No. 62 / Friday, April 1, 2005 / Notices
Dated: March 25, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–6405 Filed 3–31–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2004D–0117]
International Conference on
Harmonisation; Guidance on E2E
Pharmacovigilance Planning;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a guidance entitled ‘‘E2E
Pharmacovigilance Planning.’’ The
guidance was prepared under the
auspices of the International Conference
on Harmonisation of Technical
Requirements for Registration of
Pharmaceuticals for Human Use (ICH).
The guidance describes a method for
summarizing the important potential
and identified risks of a drug. It
proposes a structure for a
pharmacovigilance plan and sets out
principles of good practice for the
design and conduct of observational
studies. The guidance is intended to aid
in planning pharmacovigilance
activities, especially in preparation for
the early postmarketing period of a new
drug.
DATES: Submit written or electronic
comments on agency guidances at any
time.
Submit written requests for
single copies of the guidance to the
Division of Drug Information (HFD–
240), Center for Drug Evaluation and
Research, Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, or the Office of
Communication, Training, and
Manufacturers Assistance (HFM–40),
Center for Biologics Evaluation and
Research, Food and Drug
Administration, 1401 Rockville Pike,
Rockville, MD 20852–1448. The
guidance may also be obtained by mail
by calling the CBER Voice Information
System at 1–800–835–4709 or 301–827–
1800. Send one self-addressed adhesive
label to assist the office in processing
your requests. Submit written comments
on the guidance to the Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
ADDRESSES:
VerDate jul<14>2003
17:15 Mar 31, 2005
Jkt 205001
Lane, rm. 1061, Rockville, MD 20852.
Submit electronic comments to https://
www.fda.gov/dockets/ecomments. See
the SUPPLEMENTARY INFORMATION section
for electronic access to the guidance
document.
FOR FURTHER INFORMATION CONTACT:
Regarding the guidance: Paul
Seligman, Center for Drug
Evaluation and Research (HFD–
030), Food and Drug
Administration, Rockville, MD
20857, 301–827–6276, or M. Miles
Braun, Center for Biologics
Evaluation and Research (HFM–
220), 1401 Rockville Pike,
Rockville, MD 20852, 301–827–
3974.
Regarding the ICH: Michelle Limoli,
Office of International Programs
(HFG–1), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–
4480.
SUPPLEMENTARY INFORMATION:
I. Background
In recent years, many important
initiatives have been undertaken by
regulatory authorities and industry
associations to promote international
harmonization of regulatory
requirements. FDA has participated in
many meetings designed to enhance
harmonization and is committed to
seeking scientifically based harmonized
technical procedures for pharmaceutical
development. One of the goals of
harmonization is to identify and then
reduce differences in technical
requirements for drug development
among regulatory agencies.
ICH was organized to provide an
opportunity for tripartite harmonization
initiatives to be developed with input
from both regulatory and industry
representatives. FDA also seeks input
from consumer representatives and
others. ICH is concerned with
harmonization of technical
requirements for the registration of
pharmaceutical products among three
regions: The European Union, Japan,
and the United States. The six ICH
sponsors are the European Commission;
the European Federation of
Pharmaceutical Industries Associations;
the Japanese Ministry of Health, Labour,
and Welfare; the Japanese
Pharmaceutical Manufacturers
Association; the Centers for Drug
Evaluation and Research and Biologics
Evaluation and Research, FDA; and the
Pharmaceutical Research and
Manufacturers of America. The ICH
Secretariat, which coordinates the
preparation of documentation, is
provided by the International
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
16827
Federation of Pharmaceutical
Manufacturers Associations (IFPMA).
The ICH Steering Committee includes
representatives from each of the ICH
sponsors and the IFPMA, as well as
observers from the World Health
Organization, Health Canada, and the
European Free Trade Area.
In the Federal Register of March 30,
2004 (69 FR 16579), FDA published a
notice announcing the availability of a
draft tripartite guidance entitled ‘‘E2E
Pharmacovigilance Planning.’’ The
notice gave interested persons an
opportunity to submit comments by
May 19, 2004.
After consideration of the comments
received and revisions to the guidance,
a final draft of the guidance was
submitted to the ICH Steering
Committee and endorsed by the three
participating regulatory agencies in
November 2004.
The document provides guidance on
summarizing the important identified
risks of a drug, important potential
risks, and important missing
information, including the potentially
at-risk populations and situations where
the product is likely to be used that
have not been studied prior to approval.
The guidance proposes a structure for a
pharmacovigilance plan and sets out
principles of good practice for the
design and conduct of observational
studies.
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the agency’s
current thinking on this topic. It does
not create or confer any rights for or on
any person and does not operate to bind
FDA or the public. An alternative
approach may be used if such approach
satisfies the requirements of the
applicable statutes and regulations.
II. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments on the guidance at any time.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one paper copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. The guidance
and received comments may be seen in
the Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
III. Electronic Access
Persons with access to the Internet
may obtain the document at https://
www.fda.gov/ohrms/dockets/
E:\FR\FM\01APN1.SGM
01APN1
]]>Agencies
[Federal Register Volume 70, Number 62 (Friday, April 1, 2005)]
[Notices]
[Pages 16824-16827]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-6405]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2004N-0515]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Medical Device
Labeling Regulations
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by May 2,
2005.
ADDRESSES: OMB is still experiencing significant delays in the regular
mail, including first class and express mail, and messenger deliveries
are not being accepted. To ensure that comments on the information
collection are received, OMB recommends that comments be faxed to the
Office of Information and Regulatory Affairs, OMB, Attn: Fumie Yokota,
Desk Officer for FDA, FAX: 202-395-6974.
FOR FURTHER INFORMATION CONTACT: Peggy Robbins, Office of Management
Programs (HFA-250), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-827-1223.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Medical Device Labeling Regulations--21 CFR Parts 800, 801, and 809
(OMB Control Number 0910-0485)--Extension
Section 502 of the Federal Food, Drug, and Cosmetic Act (the act)
(21 U.S.C. 352), among other things, establishes requirements for the
label or labeling of a medical device so that it is not misbranded and
subject to regulatory action. Certain provisions of section 502 of the
act require that manufacturers, importers, and distributors of medical
devices disclose information about themselves or their devices on the
labels or labeling of the devices. Section 502(b) of the act requires
that, if the device is in a package, the label must contain the name
and place of business of the manufacturer, packer, or distributor and
an accurate statement of the quantity of the contents. Section 502(f)
of the act provides that the labeling of a device must contain adequate
directions for use. FDA may grant an exemption from the adequate
directions for use requirement, if FDA determines that adequate
directions for use are not necessary for the protection of the public
health.
FDA regulations in parts 800, 801, and 809 (21 CFR parts 800, 801,
and 809) require manufacturers, importers, and distributors of medical
devices to disclose to health professionals and consumers specific
information about themselves or their devices on the label or labeling
of their devices. FDA issued these regulations under the authority of
sections 201, 301, 502, and 701 of the act (21 U.S.C. 321, 331, 352,
and 371). Most of the regulations in parts 800, 801, and 809 derive
from the requirements of section 502 of the act, which provides, in
part, that a device shall be misbranded if, among other things, its
label or labeling fails to bear certain required information concerning
the device, is false or misleading in any particular way, or fails to
contain adequate directions for use.
Section 800.12 requires that packages of contact lens cleaning
solutions include a tamper-resistant feature to prevent malicious
adulteration. Sections 800.10(a)(3) and 800.12(c) require that the
label of contact lens cleaning solutions contain a prominent statement
alerting consumers to the tamper-resistant feature.
Section 800.10(b)(2) requires that the labeling of liquid
ophthalmic preparations packed in multiple-dose containers include
information as to duration of use and necessary warnings to afford
adequate protection from contamination during use.
Section 801.1 requires that the label of a device in package form
contain the name and place of business of the manufacturer, packer, or
distributor.
Section 801.5 requires that the labeling of devices include
directions under which the layman can use a device safely and for the
purposes for which it is intended. Section 801.4 defines ``intended
use''. Where necessary, the labeling should include: (1) Statements of
all conditions, purposes, or uses for which the device is intended,
unless the device is a prescription device subject to the requirements
of Sec. 801.109; (2) quantity of dose; (3) frequency of administration
or application; (4) duration of administration or application; (5) time
of administration, e.g. in relation to meals, onset of symptoms, etc.;
(6) route of method or application; and (7) preparation for use.
Section 801.61 requires that the principal display panel of an
over-the-counter (OTC) device in package form must include a statement
of the identity of the device. The statement of the identity of the
device must include the common name of the device followed by an
accurate statement of the principal intended actions of the device.
Section 801.62 requires that the label of an OTC device in package
form must include a declaration of the net quantity of contents. The
label must express the net quantity in terms of weight, measure,
numerical count, or a combination of numerical count and weight,
measure, or size.
Section 801.109 establishes labeling requirements for prescription
devices. A prescription device is defined as a device which, because of
its potential for harmful effect, the method of its use or the
collateral measures necessary to its use, is not safe except under the
supervision of a practitioner licensed by law to use the device and,
therefore, for which adequate directions for use by a layperson cannot
be developed.
The label of the device must include: (1) The statement ``Caution:
Federal law restricts this device to sale by or on the order of a `----
--------' ''. The blank is to be filled in by a term such as
``physician,'' ``dentist,'' or other appropriate term; and (2) the
method of its application or use.
Labeling must include information for use, including indications,
effects, routes, methods, frequency and duration of administration, and
any relevant hazards, contraindications, side effects, and precautions
under which practitioners licensed by law to administer the device can
use the device safely and for the purpose for which it is intended,
including all purposes for which it is advertised or represented.
Information may be omitted from the dispensing package if, but only
if, the article is a device for which directions, hazards, warnings,
and other information are commonly known to practitioners licensed by
law to use the device.
Section 801.110 establishes a labeling requirement for a
prescription device delivered to the ultimate purchaser or user upon
the prescription of a licensed practitioner. The device must be
accompanied by labeling bearing the name and address of the licensed
[[Page 16825]]
practitioner and the directions for use and cautionary statements, if
any, contained in the order.
Section 801.405 establishes labeling requirements for articles
intended for lay use in repairing and refitting dentures. The labeling
must: (1) Limit directions for use for denture repair kits to emergency
repair pending unavoidable delay in obtaining professional
reconstruction of the denture; (2) limit directions for use for denture
reliners, pads, and cushions to temporary refitting pending unavoidable
delay in obtaining professional reconstruction of the denture; and (3)
contain the word ``emergency'' preceding and modifying each indication-
for-use statement for denture repair kits and the word ``temporary''
preceding and modifying each indication-for-use statement for reliners,
pads, and cushions.
Section 801.410(f) requires that results of impact tests and
description of the test method and apparatus be kept for a period of 3
years.
Section 801.410(f) is designed to protect the eyeglass wearer from
potential eye injury resulting from shattering of ordinary eyeglass
lenses and requires that eyeglasses and sunglasses be fitted with
impact-resistant lenses. Examination of data available on the frequency
of eye injuries resulting from the shattering of ordinary crown glass
lenses indicates that the use of such lenses constitutes an avoidable
hazard to the eye of the wearer. According to the Vision Council of
America, 60 percent of the population, or 161 million Americans, wear
prescription eyewear; 81 percent have eyeglasses, 3 percent have
contact lenses only; and 16 percent have both eyeglasses and contact
lenses.
Section 801.420(c) requires that the manufacturers or distributors
of hearing aids develop a User Instructional Brochure, which
accompanies the device and is provided to the prospective user by the
dispenser of the hearing aid. The brochure must contain detailed
information on the use and maintenance of the hearing aid.
Section 801.421(b) requires the hearing aid dispenser to provide
the prospective user a copy of the User Instructional Brochure and an
opportunity to review the comments with him/her orally or in the
predominant method of communication used during the sale.
Section 801.421(c) requires the hearing aid dispenser to provide,
upon request, to the prospective purchaser of any hearing aid (s)he
dispenses, a copy of the User Instructional Brochure or the name and
address of the manufacturer or distributor from whom the brochure may
be obtained.
Section 801.421(d) requires the hearing aid dispenser to retain
copies of all physician statements or any waivers of medical evaluation
for 3 years from the time of dispensing.
Section 801.435 requires condom manufacturers to include an
expiration date in the labeling of the condom. The manufacturer must
support the expiration date by data from quality control tests
demonstrating physical and mechanical integrity of three random lots of
the same product which were stored under accelerated and real time
conditions.
Section 809.10(a) provides that a label for an in vitro diagnostic
product must contain the following information:
1. The proprietary and established name;
2. The intended use or uses of the product;
3. For a reagent, a declaration of the established name, if any,
and the quantity, proportion, and concentration of each reactive
ingredient;
4. A statement of warnings and precautions for users;
5. For a reagent, appropriate storage instructions;
6. For a reagent, a means by which the user may be assured that the
product meets the appropriate standards of identity, strength, quality,
and purity;
7. For a reagent, a declaration of the net quantity of contents;
8. Name and place of business of the manufacturer, packer, and
distributor; and
9. A lot or control number.
Section 809.10(b) provides that the labeling (package insert)
accompanying the device must contain the following:
1. Proprietary name and established name, if any;
2. The intended use or uses;
3. A summary and explanation of the test;
4. The chemical, physical, physiological, or biological principles
of the procedure;
5. Information about the reagents;
6. Information about the instruments;
7. Information about the specimen collection and preparation for
analysis;
8. Information about the procedure;
9. Information about the results;
10. Information about the limitations of the procedure;
11. Expected values;
12. Specific performance characteristics;
13. A bibliography of pertinent references; and
14. Date of issuance of the last revision of the labeling.
Section 809.10(d) provides that the labeling for general purpose
laboratory reagents may be exempt from the labeling requirements in
Sec. 809.10(a) and (b), if the labeling contains the following:
1. The proprietary name and established name of the reagent;
2. The established name and the quantity, proportion, and
concentration of the reagent ingredient;
3. A statement of the purity and quality of the reagent;
4. A statement of warnings and precautions for users;
5. Appropriate storage instructions;
6. A declaration of the net quantity of contents;
7. Name and place of business of the manufacturer, packer, or
distributor; and
8. A lot or control number.
Section 809.10(e) requires manufacturers of analyte specific
reagents to include the following in the labeling:
1. The proprietary name and established name, if any, of the
reagent;
2. A declaration of established name, if any, and quantity,
proportion or concentration of the reagent ingredient;
3. A statement of the purity and quality of the reagent;
4. A statement of warnings or precautions for users;
5. Appropriate storage instructions;
6. A declaration of the net quantity of contents;
7. Name and place of business of the manufacturer, packer, or
distributor;
8. A lot or control number; and
9. The statement, ``For analyte specific reagent use only.
Analytical and performance characteristics are not established.''
Section 809.10(f) requires that the labeling for OTC test sample
collection systems for drugs of abuse testing bear the following
information in a language appropriate for the intended users:
1. Adequate instructions for specimen collection and handling;
2. An identification system to ensure that specimens are not mixed
up or otherwise misidentified at the laboratory;
3. The intended use or uses of the product;
4. A statement that confirmatory testing will be conducted on all
samples that initially test positive;
5. A statement of warnings or precautions for users;
6. Adequate instructions on how to obtain test results from a
person who can explain their meaning, including the probability of
false positive and false negative results, as well as how to contact a
trained health professional if additional information on interpretation
of test results or followup counseling is desired; and
[[Page 16826]]
7. Name and place of business of the manufacturer, packer, or
distributor.
Section 809.30(d) requires that manufacturers of analyte specific
reagents (ASRs) assure that advertising and promotional materials for
ASRs:
1. Include the identity and purity of the ASR and the identity of
the analyte; and
2. Do not include any statement regarding analytical or clinical
performance.
These estimates are based on FDA's registration and listing
database for medical device establishments, agency communications with
industry, and FDA's knowledge of and experience with device labeling.
We have not estimated a burden for those requirements where the
information to be disclosed is information that has been supplied by
FDA. Also, we have not estimated a burden for that information that is
disclosed to third parties as a usual and customary part of a medical
device manufacturer, distributor, or importer's normal business
activities. We do not include any burden for time that is spent
designing labels to improve the format or presentation.
In the Federal Register of December 14, 2004 (69 FR 74529), FDA
published a 60-day notice requesting public comment on the information
collection provisions. No comments were received.
FDA estimates the burden of this collection of information as
follows:
Table 1.--Estimated Annual Reporting Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Annual Responses Per Total Annual Hours per
21 CFR Section No. of Respondents Respondent Responses Response Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
800.10(a)(3) and 800.12(c) 4 10 40 1 40
--------------------------------------------------------------------------------------------------------------------------------------------------------
800.10(b)(2) 4 10 40 40 1,600
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.1 30,000 3.5 105,000 0.1 10,500
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.5 5,000 3.5 17,500 22.35 391,125
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.61 5,000 3.5 17,500 1 17,500
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.62 1,000 5 5,000 1 5,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.109 18,000 3.5 63,000 17.77 1,119,510
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.110 10,000 50 500,000 0.25 125,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.405(b) 40 1 40 4 160
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.420(c) 275 5 1,375 40 55,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.421(b) 10,000 160 1,600,000 0.30 480,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.421(c) 10,000 5 50,000 0.17 8,500
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.435 135 1 135 96 12,960
--------------------------------------------------------------------------------------------------------------------------------------------------------
809.10(a) and (b) 1,700 6 10,200 80 816,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
809.10(d) 300 2 600 40 24,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
809.10(e) 300 25 7,500 1 7,500
--------------------------------------------------------------------------------------------------------------------------------------------------------
809.10(f) 20 1 20 100 2,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
809.30(d) 300 25 7,500 1 7,500
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total Burden Hours ......................... ......................... .............. .............. 3,083,895
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this information collection.
Table 2.--Estimated Annual Recordkeeping Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Annual Frequency of Total Annual Hours per
21 CFR Section No. of Recordkeepers Recordkeeping Records Recordkeeper Total hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.410(f) 30 769,000 23,070,000 641 19,225
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.421(d) 10,000 160 1,600,000 0.25 400,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total Hours ......................... ......................... .............. .............. 419,225
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this information collection.
[[Page 16827]]
Dated: March 25, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05-6405 Filed 3-31-05; 8:45 am]
BILLING CODE 4160-01-S
